| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines.
|
Bone Marrow Transplant
|
2001
|
1.66
|
|
2
|
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution.
|
Ann Oncol
|
1996
|
1.45
|
|
3
|
Persistent changes in the immune system 4-10 years after ABMT.
|
Bone Marrow Transplant
|
1999
|
1.44
|
|
4
|
Follow-up of breast cancer patients stage I-II: a baseline strategy.
|
Eur J Cancer
|
1993
|
1.39
|
|
5
|
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.
|
J Clin Oncol
|
1993
|
1.35
|
|
6
|
Extramedullary plasmacytomas and solitary plasma cell tumours of bone.
|
Eur J Haematol
|
1990
|
1.07
|
|
7
|
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time.
|
Ann Oncol
|
2002
|
1.02
|
|
8
|
High level of fatigue in lymphoma patients treated with high dose therapy.
|
J Pain Symptom Manage
|
2000
|
0.96
|
|
9
|
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.
|
Eur J Cancer
|
1990
|
0.96
|
|
10
|
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival.
|
Scand J Haematol
|
1985
|
0.96
|
|
11
|
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas.
|
Scand J Haematol
|
1981
|
0.93
|
|
12
|
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas.
|
Int J Cancer
|
1984
|
0.92
|
|
13
|
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial.
|
Med Oncol
|
2001
|
0.92
|
|
14
|
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.
|
Bone Marrow Transplant
|
2005
|
0.91
|
|
15
|
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.
|
Int J Cancer
|
1989
|
0.91
|
|
16
|
Hodgkin's disease in a national and hospital population: trends over 20 years.
|
Eur J Cancer
|
1997
|
0.89
|
|
17
|
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
|
Eur J Cancer Clin Oncol
|
1986
|
0.87
|
|
18
|
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
|
Bone Marrow Transplant
|
2001
|
0.87
|
|
19
|
Cellular antitumor immune response in women with risk factors for breast cancer.
|
Cancer Res
|
1979
|
0.87
|
|
20
|
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
|
Ann Hematol
|
2004
|
0.87
|
|
21
|
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial.
|
Ann Oncol
|
1999
|
0.86
|
|
22
|
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution.
|
Eur J Cancer
|
1998
|
0.85
|
|
23
|
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
|
Br J Haematol
|
2004
|
0.84
|
|
24
|
A population-based study of spinal metastatic disease in South-East Norway.
|
Clin Oncol (R Coll Radiol)
|
2009
|
0.83
|
|
25
|
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
|
Eur J Haematol
|
2004
|
0.83
|
|
26
|
Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry.
|
Acta Pathol Microbiol Scand A
|
1981
|
0.83
|
|
27
|
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
|
Cytotherapy
|
2001
|
0.81
|
|
28
|
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas.
|
Int J Cancer
|
1987
|
0.80
|
|
29
|
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease.
|
Acta Oncol
|
1999
|
0.80
|
|
30
|
[Diagnosis and treatment of solitary plasmacytoma].
|
Tidsskr Nor Laegeforen
|
1990
|
0.80
|
|
31
|
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
|
Bone Marrow Transplant
|
2001
|
0.80
|
|
32
|
[The radiotherapy satellite in Kristiansand--a model for Norwegian regional hospitals?].
|
Tidsskr Nor Laegeforen
|
2001
|
0.79
|
|
33
|
Pain after palliative radiotherapy for spine metastases.
|
Clin Oncol (R Coll Radiol)
|
2010
|
0.79
|
|
34
|
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers.
|
Acta Oncol
|
1999
|
0.79
|
|
35
|
Immunoblastic lymphadenopathy with early onset in two boys: immunohistochemical study and indication of decreased proportion of circulating T-helper cells.
|
Br J Haematol
|
1984
|
0.78
|
|
36
|
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
|
Eur J Haematol Suppl
|
2001
|
0.77
|
|
37
|
Purging of tumor cells from leukapheresis products: experimental and clinical aspects.
|
J Hematother
|
1996
|
0.77
|
|
38
|
Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation.
|
J Natl Cancer Inst
|
1988
|
0.77
|
|
39
|
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement.
|
Acta Radiol
|
1997
|
0.77
|
|
40
|
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
|
Bone Marrow Transplant
|
1998
|
0.77
|
|
41
|
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas.
|
Br J Cancer
|
1998
|
0.77
|
|
42
|
Bone marrow examination in Hodgkin's disease.
|
Acta Oncol
|
1992
|
0.76
|
|
43
|
An effective immunomagnetic method for bone marrow purging in T cell malignancies.
|
Bone Marrow Transplant
|
1992
|
0.76
|
|
44
|
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood].
|
Tidsskr Nor Laegeforen
|
1996
|
0.75
|
|
45
|
[Giant cell anaplastic anemia].
|
Tidsskr Nor Laegeforen
|
1989
|
0.75
|
|
46
|
Distribution of T-cell subsets identified by monoclonal antibodies in cell suspensions from lymph node biopsies of human B-cell lymphomas.
|
Scand J Haematol
|
1982
|
0.75
|
|
47
|
Quantitative comparison of Epstein-Barr virus receptor expression on sIgM and sIgG cell lines and B-cell lymphoma biopsies.
|
Differentiation
|
1982
|
0.75
|
|
48
|
Stage I high-grade non-Hodgkin's lymphoma.
|
Acta Oncol
|
2000
|
0.75
|
|
49
|
[Ovarian irridation and prednisone versus tamoxifen (Nolvadex) in advanced breast cancer].
|
Tidsskr Nor Laegeforen
|
1983
|
0.75
|
|
50
|
[Antibody synthesis biology. A theme with variations--from amino acid sequence and regulatory cell circuits to malignant lymphomas].
|
Tidsskr Nor Laegeforen
|
1980
|
0.75
|
|
51
|
Prognostic variables and results of salvage treatment in Hodgkin's disease.
|
Acta Oncol
|
1996
|
0.75
|
|
52
|
Immunologic subsets in B cell lymphomas defined by surface immunoglobulin isotype and complement receptor--their relationship to survival.
|
Scand J Haematol
|
1985
|
0.75
|
|
53
|
[Non-Hodgkin's lymphoma in the gastrointestinal tract].
|
Tidsskr Nor Laegeforen
|
1991
|
0.75
|
|
54
|
Sézary cells with an unusual phenotype, their modulation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) in vitro, and their relationship to T-cell development.
|
J Clin Immunol
|
1983
|
0.75
|
|
55
|
[Monoclonal antibodies. A new tool in the diagnosis of leukemia and lymphoma].
|
Tidsskr Nor Laegeforen
|
1985
|
0.75
|
|
56
|
[Primary non-Hodgkin's lymphoma of the brain].
|
Tidsskr Nor Laegeforen
|
1998
|
0.75
|
|
57
|
Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study.
|
Ann Oncol
|
1994
|
0.75
|
|
58
|
[Tissue necrosis caused by careless injection of cytostatic agents].
|
Tidsskr Nor Laegeforen
|
1978
|
0.75
|
|
59
|
[High-dose therapy of cancer with CD34 positive cells as stem cell support].
|
Tidsskr Nor Laegeforen
|
1996
|
0.75
|
|
60
|
[Tumor lysis syndrome. A life-threatening complication during cytostatic treatment of chemosensitive types of cancer].
|
Tidsskr Nor Laegeforen
|
1991
|
0.75
|
|
61
|
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma.
|
Bone Marrow Transplant
|
1996
|
0.75
|
|
62
|
[The importance of nutrition for cancer patients].
|
Tidsskr Nor Laegeforen
|
1998
|
0.75
|
|
63
|
Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas.
|
Br J Haematol
|
1993
|
0.75
|
|
64
|
Influence of progestogen therapy on T lymphocyte subsets.
|
Acta Pathol Microbiol Immunol Scand C
|
1984
|
0.75
|
|
65
|
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily.
|
Scand J Immunol
|
2011
|
0.75
|
|
66
|
[Check up of breast cancer stages 1 and 2].
|
Tidsskr Nor Laegeforen
|
1997
|
0.75
|